ESSA Pharma

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It focuses on developing novel and proprietary therapies for the treatment of prostate cancer in patients, whose disease is progressing despite treatment with standard of care therapies, including second-generation anti-androgen drugs such as abiraterone, enzalutamide, apalutamide and darolutamide. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Ambev

Ginkgo Bioworks Holdings

Nokia

Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Beginner Penny Stocks Trading Mistakes

Cosmos Holdings

RLX Technology

SINTX Technologies Inc

Use these strategies for making money with penny stocks The post Top Strategies for Making Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Strategies for Making Money With Penny Stocks

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data for its lead first generation androgen receptor ("AR") ANITen bAsed Chimera ("ANITAC"™) N-terminal domain ("NTD") degrader in a poster session at the 34th EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The preclinical data demonstrate that EPI-8207, an ANITAC, shows robust potency degrading AR, including AR splice variants and clinically relevant AR mutants that can potentially drive disease progression in patients with castration-resistant prostate cancer ("CRPC").

ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

ESSA Pharma (NASDAQ: EPIX ) stock is flying higher on Wednesday following the release of data from a Phase 1/2 study of EPI-7386. EPI-7386 is a drug in development for the treatment of metastatic castration-resistant prostate cancer.

Why Is ESSA Pharma (EPIX) Stock Up 156% Today?

EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA's lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC"). Data will be presented in a poster format at the 2022 Prostate Cancer Foundation ("PCF") Scientific Retreat, taking place October 27-29, 2022 in Carlsbad, CA.

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D.

ESSA Pharma Appoints Philip Kantoff to its Board of Directors

Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has not conducted a conference call to better explain the clinical trial situation.

ESSA Pharma Inc.: Selling For Under Cash Value

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022

Bed Bath & Beyond

BitNile Holdings

Insiders love these 3 penny stocks in July 2022 The post 3 Best Penny Stocks To Buy According To Insiders; 1 Bet Over $1.7 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Best Penny Stocks To Buy According To Insiders; 1 Bet Over $1.7 Million

EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 27, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented clinical results from the Phase 1a dose escalation study of EPI-7386, ESSA's first-in-class N-terminal domain ("NTD") androgen receptor ("AR") inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer ("mCRPC") resistant to current standard-of-care therapies.

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 3:00 p.m. Eastern Time.

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2022.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders inhibit AR-dependent transcription and reduce viability of AR-dependent prostate cancer cells Data to be presented at the 2022 American Association for Cancer Research Annual Meeting SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, BC , April 8, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data for its first generation of androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting. "We look forward to presenting our first preclinical data demonstrating the potential of ESSA's ANITAC degraders as a new approach to AR pathway inhibition.

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANIT en bAsed Chimera (ANITAC™) degraders degrade full length, mutant and splice variant forms of AR that are expressed in CRPC patients Orally bioavailable ANITAC degraders show robust functional activity in cellular models including inhibition of AR transcriptional activity and cell viability SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , March 8, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it will present preclinical data for its first generation of androgen receptor (AR) N-terminal domain degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The ANITen bAsed Chimera (ANITAC™) degraders suppressed AR transcriptional activity and decreased the viability of prostate cancer cells in castration-resistant prostate cancer (CRPC) preclinical models.

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

HOUSTON, Texas and VANCOUVER, Canada, Feb. 3, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021

HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma Inc.'s ("Astellas") and Pfizer Inc.'s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer ("mCRPC"). "The initiation of this combination trial with Astellas is a watershed moment for ESSA as we investigate the potential clinical benefit of inhibiting the androgen receptor through two independent pathways in the treatment of patients with mCRPC who have not yet received treatment with a second-generation antiandrogen drug," said Dr. David.

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

VANCOUVER, Canada and HOUSTON, Texas, Nov. 18, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021

ESSA Pharma developed a novel mode of action drug, EPI-7386, for the treatment of metastatic castrate-resistant prostate cancer. Pre-clinical and early Ph 1 results are promising. ESSA's share price crashed in mid-Aug when a change in the Ph 1 trial protocol was announced, and a delay in the expected Ph 1 monotherapy trial data release. I believe the market overreacted.

ESSA Pharma: Why I Remain Bullish

VANCOUVER, Canada and HOUSTON, Texas, Nov. 8, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings at three upcoming virtual investor conferences.

ESSA Pharma to Participate in Three Upcoming Investor Conferences

VANCOUVER , Canada and HOUSTON , Texas, Oct. 28, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.

ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat

-       Data presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics – VANCOUVER, Canada and HOUSTON, Texas, Oct. 7, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA's lead product candidate for the treatment of prostate cancer. The data include the results of nuclear magnetic resonance (NMR) studies which confirm the binding of the compound to the N-terminal domain (NTD) of the androgen receptor (AR), a region not currently targeted by other antiandrogen therapies.

ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386

IRVING, Texas, and HOUSTON, and VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ --  Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today a Precision Development program to support ESSA's ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer ("mCRPC") failing current standard-of-care therapies. Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform.

Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration

VANCOUVER, Canada and HOUSTON, Texas, Aug. 31, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will be presenting and hosting one-on-one meetings with investors at two upcoming virtual investor conferences.

News for ESSA Pharma Stock (EPIX)